Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abortion Safety and Use with Normally Prescribed Mifepristone in Canada

Open access
Schummers, Laura, Darling, Elizabeth K., Dunn, Sheila, McGrail, Kimberlyn, Gayowsky, Anastasia, Law, Michael R., Laba, Tracey-Lea, Kaczorowski, Janusz, Norman, Wendy V. · 2022 · New England Journal of Medicine

Abstract

BACKGROUND: In the United States, mifepristone is available for medical abortion (for use with misoprostol) only with Risk Evaluation and Mitigation Strategy (REMS) restrictions, despite an absence of evidence to support such restrictions. Mifepristone has been available in Canada with a normal prescription since November 2017. METHODS: Using population-based administrative data from Ontario, Canada, we examined abortion use, safety, and effectiveness using an interrupted time-series analysis comparing trends in incidence before mifepristone was available (January 2012 through December 2016) with trends after its availability without restrictions (November 7, 2017, through March 15, 2020). RESULTS: A total of 195,183 abortions were performed before mifepristone was available and 84,032 after its availability without restrictions. After the availability of mifepristone with a normal prescription, the abortion rate continued to decline, although more slowly than was expected on the basis of trends before mifepristone had been available (adjusted risk difference in time-series analysis, 1.2 per 1000 female residents between 15 and 49 years of age; 95% confidence interval [CI], 1.1 to 1.4), whereas the percentage of abortions provided as medical procedures increased from 2.2% to 31.4% (adjusted risk difference, 28.8 percentage points; 95% CI, 28.0 to 29.7). There were no material changes between the period before mifepristone was available and the nonrestricted period in the incidence of severe adverse events (0.03% vs. 0.04%; adjusted risk difference, 0.01 percentage points; 95% CI, -0.06 to 0.03), complications (0.74% vs. 0.69%; adjusted risk difference, 0.06 percentage points; 95% CI, -0.07 to 0.18), or ectopic pregnancy detected after abortion (0.15% vs. 0.22%; adjusted risk difference, -0.03 percentage points; 95% CI, -0.19 to 0.09). There was a small increase in ongoing intrauterine pregnancy continuing to delivery (adjusted risk difference, 0.08 percentage points; 95% CI, 0.04 to 0.10). CONCLUSIONS: After mifepristone became available as a normal prescription, the abortion rate remained relatively stable, the proportion of abortions provided by medication increased rapidly, and adverse events and complications remained stable, as compared with the period when mifepristone was unavailable. (Funded by the Canadian Institutes of Health Research and the Women's Health Research Institute.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmsa2109779

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1197/j.aem.2004.11.018 · doi:10.1197/j.aem.2004.11.018 · Paper page

Cited by

See all 77

Metadata

Authors
Schummers, L., Darling, E. K., Dunn, S., McGrail, K., Gayowsky, A., Law, M. R., Laba, T.-L., Kaczorowski, J., & Norman, W. V.
Affiliations
University of British Columbia (CA)
Venue
New England Journal of Medicine
Published
2022-01-06
Volume
386
Issue
1
Pages
57-67
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4200143757
Cited by
71
References
31
Citations by year
2026: 8 · 2025: 22 · 2024: 9 · 2023: 19 · 2022: 12
FWCI
8.88
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders
  • Institute of Health Services and Policy Research (Canada Chair in Prevention and Control of Hyperten, Early Career Researcher: ECI-167971, Health System Impact Fellowship 2018 Schummers, Patient-Oriented Research Award – Transition to, Project Grant PJT-168964 2020-24, Public Health Research Chair: CPP-329455-107837 20)
  • British Columbia Ministry of Health (18183)
  • Michael Smith Foundation for Health Research (17934, 2012-5139 HSR)
  • Canada Research Chairs (Canada Research Chair in Access to Medicines)
  • National Health and Medical Research Council (Early Career Fellowship (APP1110230))
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
mifepristone, abortion pills, abortion safety, risk evaluation and mitigation strategy, drug regulation, prescribing restrictions, misoprostol, Canada

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.